Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

亚胺培南/西司他丁 医学 碳青霉烯 头孢菌素 鲍曼不动杆菌 泌尿系统 内科学 随机对照试验 临床终点 不利影响 亚胺培南 重症监护医学 抗生素 西司他丁 铜绿假单胞菌 微生物学 抗生素耐药性 生物 细菌 遗传学
作者
Simon Portsmouth,David Friedrich Van Veenhuyzen,ROGER M. ECHOLS,Mitsuaki Machida,Juan Camilo Arjona Ferreira,Mari Ariyasu,Peter Tenke,Tsutae Den Nagata
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:18 (12): 1319-1328 被引量:454
标识
DOI:10.1016/s1473-3099(18)30554-1
摘要

Background Carbapenem-resistant Gram-negative bacteria represent the highest priority for addressing global antibiotic resistance. Cefiderocol (S-649266), a new siderophore cephalosporin, has broad activity against Enterobacteriaceae and non-fermenting bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, including carbapenem-resistant strains. We assessed the efficacy and safety of cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infection in patients at risk of multidrug-resistant Gram-negative infections. Methods We did a phase 2, multicentre, double-blind, parallel-group non-inferiority trial at 67 hospitals in 15 countries. Adults (≥18 years) admitted to hospital with a clinical diagnosis of complicated urinary tract infection with or without pyelonephritis or those with acute uncomplicated pyelonephritis were randomly assigned (2:1) by an interactive web or voice response system to receive 1 h intravenous infusions of cefiderocol (2 g) or imipenem-cilastatin (1 g each) three times daily, every 8 h for 7–14 days. Patients were excluded if they had a baseline urine culture with more than two uropathogens, a fungal urinary tract infection, or pathogens known to be carbapenem resistant. The primary endpoint was the composite of clinical and microbiological outcomes at test of cure (ie, 7 days after treatment cessation), which was used to establish non-inferiority (15% and 20% margins) of cefiderocol versus imipenem-cilastatin. The primary efficacy analysis was done on a modified intention-to-treat population, which included all randomly assigned individuals who received at least one dose of study drug and had a qualifying Gram-negative uropathogen (≥1 × 105 colony-forming units [CFU]/mL). Safety was assessed in all randomly assigned individuals who received at least one dose of study drug, according to the treatment they received. This study is registered with ClinicalTrials.gov, number NCT02321800. Findings Between Feb 5, 2015, and Aug 16, 2016, 452 patients were randomly assigned to cefiderocol (n=303) or imipenem-cilastatin (n=149), of whom 448 patients (n=300 in the cefiderocol group; n=148 in the imipenem-cilastatin group) received treatment. 371 patients (n=252 patients in the cefiderocol group; n=119 patients in the imipenem-cilastatin group) had qualifying Gram-negative uropathogen (≥1 × 105 CFU/mL) and were included in the primary efficacy analysis. At test of cure, the primary efficacy endpoint was achieved by 183 (73%) of 252 patients in the cefiderocol group and 65 (55%) of 119 patients in the imipenem-cilastatin group, with an adjusted treatment difference of 18·58% (95% CI 8·23–28·92; p=0·0004), establishing the non-inferiority of cefiderocol. Cefiderocol was well tolerated. Adverse events occurred in 122 (41%) of 300 patients in the cefiderocol group and 76 (51%) of 148 patients in the imipenem-cilastatin group, with gastrointestinal disorders (ie, diarrhoea, constipation, nausea, vomiting, and abdominal pain) the most common adverse events for both treatment groups (35 [12%] patients in the cefiderocol group and 27 [18%] patients in the imipenem-cilastatin group). Interpretation Intravenous infusion of cefiderocol (2 g) three times daily was non-inferior compared with imipenem-cilastatin (1 g each) for the treatment of complicated urinary tract infection in people with multidrug-resistant Gram-negative infections. The results of this study will provide the basis for submission of a New Drug Application to the US Food and Drug Administration. Clinical trials of hospital-acquired pneumonia and carbapenem-resistant infections are ongoing. Funding Shionogi & Co Ltd, Shionogi Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
大模型的应助被Temperance采纳,获得10
1秒前
独特十三完成签到,获得积分10
1秒前
田様的应助被Code_king采纳,获得10
1秒前
CipherSage的应助被Code_king采纳,获得10
1秒前
苗条的芒果完成签到,获得积分10
1秒前
隐形曼青的应助被Code_king采纳,获得10
1秒前
orixero的应助被Code_king采纳,获得10
1秒前
小蘑菇的应助被Code_king采纳,获得10
2秒前
丘比特的应助被Code_king采纳,获得10
2秒前
Ava的应助被gyq采纳,获得10
2秒前
2秒前
xiangpica发布了新的文献求助10
3秒前
3秒前
3秒前
ding的应助被坚定的问芙采纳,获得10
3秒前
3秒前
4秒前
4秒前
哇与哈哈完成签到,获得积分10
4秒前
4秒前
徐嘉女完成签到,获得积分10
4秒前
乘方完成签到,获得积分10
4秒前
多多发布了新的文献求助10
4秒前
Daisykiller完成签到,获得积分10
5秒前
5秒前
5秒前
5秒前
5秒前
感动函完成签到,获得积分10
6秒前
无花果的应助被CengcEng采纳,获得10
6秒前
tang发布了新的文献求助10
6秒前
Max完成签到,获得积分10
6秒前
深情安青的应助被yzc采纳,获得10
6秒前
隐形曼青的应助被Code_king采纳,获得10
7秒前
迷风完成签到,获得积分10
7秒前
molihuakai的应助被jyliu采纳,获得10
7秒前
852的应助被Code_king采纳,获得10
7秒前
小马甲的应助被鸭脖辣不辣采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176573
求助须知:如何正确求助?哪些是违规求助? 9567927
关于积分的说明 21795369
捐赠科研通 7771232
什么是DOI,文献DOI怎么找? 3432070
关于科研通互助平台的介绍 2556429
邀请新用户注册赠送积分活动 2477707